(Q38017732)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Overcoming treatment resistance in HER2-positive breast cancer: potential strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Alessandro Marco Minisini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Carmine De Angelis

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Grazia Arpino

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

1175-1193

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22686613%20AND%20SRC:MED&resulttype=core&format=json

Gene-expression signatures in breast cancer

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Mechanism of action of trastuzumab and scientific update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

c-Cbl is a suppressor of the neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Prognostic value of ERBB family mRNA expression in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

A novel splice variant of HER2 with increased transformation activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Role of exon-16-deleted HER2 in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Differences underlying EGFR and HER2 oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634000-000000000-00000

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

21 January 2018

1 reference

12 December 2020

Mutation of the PIK3CA gene in ovarian and breast cancer

1 reference

12 December 2020

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

1 reference

12 December 2020

Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

1 reference

12 December 2020

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer

1 reference

12 December 2020

Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo

1 reference

12 December 2020

NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer

1 reference

12 December 2020

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

1 reference

12 December 2020

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

1 reference

12 December 2020

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

1 reference

12 December 2020

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

12 December 2020

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

The "other" signaling of trastuzumab: antibodies are immunocompetent drugs

1 reference

12 December 2020

Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

1 reference

12 December 2020

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

12 December 2020

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo

1 reference

12 December 2020

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells

1 reference

12 December 2020

HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy

1 reference

12 December 2020

Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer

1 reference

12 December 2020

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

12 December 2020